Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCMSC-Exo for Chemotherapy-Induced Myelosuppression in AML
NCT06245746Phase 1Recruiting
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umbilical cord derived mesenchymal stem cells exosomes in myelosuppression. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at 1 year, Dose-limiting toxicities at 14 days and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
umbilical cord derived mesenchymal stem cells exosomes
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT06245746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245746.